Use of Ovarian Tumor Markers in Prediction of Malignancy Risk in Pediatric and Adolescent Patients
Topic overview
Multi-institutional study of 309 pediatric patients identifies optimal tumor marker combinations for preoperative malignancy risk assessment in ovarian masses. Beta-HCG emerged as essential across best-performing panels, with AFP/β-HCG/CA-125/inhibin A achieving 100% negative predictive value to guide ovary-sparing decisions.
Key takeaways
- β-HCG was present in all best-performing tumor marker combinations for predicting ovarian malignancy in pediatric patients.
- The combination α-fetoprotein/β-HCG/CA-125/inhibin A achieved 100% negative predictive value, missing zero malignancies.
- Accurate preoperative risk stratification enables ovary-sparing surgery and reduces unnecessary oophorectomy for benign disease.
- Among 309 patients aged 6-21 with ovarian masses, only 25 (8%) had malignancy, highlighting importance of avoiding overtreatment.
- Multi-marker panels outperform single markers; β-HCG/inhibin A/LDH combination achieved 95.1% accuracy for malignancy prediction.
Comments